Pharmacogenetic Markers for Metabolic Impairments in Treatment with Valproic Acid

This review presents studies of the association between the use of sodium valproate formulations and increases in body weight in patients with epilepsy, as well as other valproate-induced side effects, including insulin resistance.

Saved in:
Bibliographic Details
Published inNeuroscience and behavioral physiology Vol. 50; no. 1; pp. 13 - 19
Main Authors Drokov, A. P., Lipatova, L. V., Shnayder, N. A., Nasyrova, R. F.
Format Journal Article
LanguageEnglish
Published New York Springer US 2020
Springer Nature B.V
Subjects
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Body weight
Epilepsy
Health risk assessment
Insulin
Insulin resistance
Metabolic disorders
Neurobiology
Neurosciences
Sodium valproate
Valproic acid
adipokines
undesirable side effects
valproic acid
metabolic impairments
insulin resistance
obesity
Online AccessGet full text

Cover

More Information
Summary:This review presents studies of the association between the use of sodium valproate formulations and increases in body weight in patients with epilepsy, as well as other valproate-induced side effects, including insulin resistance.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-019-00861-6